Lumos Pharma Receives $34,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=bbb4782a-ae0f-406f-9b0f-60bad94a56ba - Date
4/6/2016 - Company Name
Lumos Pharma - Mailing Address
4200 Marathon Blvd. Austin, TX 78756 USA - Company Description
Lumos Pharma, based in Austin, Texas, is an early stage biotechnology company created to develop and commercialize a novel treatment for the rare disease Creatine Transporter Deficiency. - Website
http://www.lumos-pharma.com - Transaction Type
Venture Equity - Transaction Amount
$34,000,000 - Transaction Round
Series B - Proceeds Purposes
Lumos will use the proceeds for clinical trials and commercialization of its lead compound, LUM-001, for the treatment of Creatine Transporter Deficiency (CTD). Funding will also be used to further develop other therapeutics in the company’s pipeline. - M&A Terms
- Venture Investor
Deerfield Capital - Venture Investor
New Enterprise Associates - Venture Investor
Sante Ventures - Venture Investor
Clarus Ventures - Venture Investor
Roche Venture Fund - Venture Investor
UCB S.A.
